Filtered By:
Specialty: Hematology
Condition: Bleeding
This page shows you your search results in order of relevance. This is page number 7.
Order by Relevance | Date
Total 643 results found since Jan 2013.
Risk of thromboembolic and bleeding outcomes following hematological cancers: a Danish population-based cohort study.
CONCLUSIONS: Approximately 2 out of 10 hematological cancer patients experienced MI, ischemic stroke, VTE, or bleeding requiring hospital contact within 10 years. The hematological cancer cohort had higher hazards of MI, ischemic stroke, VTE, and bleeding requiring hospital contact than a general population comparison cohort. This article is protected by copyright. All rights reserved.
PMID: 31054195 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - May 3, 2019 Category: Hematology Authors: Adelborg K, Corraini P, Darvalics B, Frederiksen H, Ording A, Horváth-Puhó E, Rørth M, Sørensen HT Tags: J Thromb Haemost Source Type: research
Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD-AF Registry
CONCLUSIONS: Patients who discontinued (n=3,114, 13.0%) had a higher risk (Hazard ratio [95% CI]) of all-cause death (1.62 [1.25-2.09]), stroke/systemic embolism (SE) (2.21 [1.42-3.44]) and myocardial infarction (MI) (1.85 [1.09-3.13]) than patients who did not, whether OAC was restarted or not. This higher risk of outcomes after discontinuation was similar for patients treated with vitamin K antagonists (VKA) and direct oral anticoagulants (DOACs) (p for interactions range=0.145-0.778). Bleeding history (1.43 [1.14-1.80]), paroxysmal vs. persistent AF (1.15 [1.02-1.29]), emergency room care setting vs. office (1.37 [1.18-...
Source: Thrombosis and Haemostasis - June 1, 2021 Category: Hematology Authors: Frank Cools Dana Johnson A John Camm Jean-Pierre Bassand Freek W A Verheugt Shu Yang Anastasios Tsiatis David A Fitzmaurice Samuel Z Goldhaber Gloria Kayani Shinya Goto Sylvia Haas Frank Misselwitz Alexander G G Turpie Keith A A Fox Karen S Pieper Ajay K Source Type: research
Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative claims databases
ConclusionsIn this real-world analysis of a large sample of NVAF patients with prior bleeding, NOACs were associated with similar or lower risk of stroke/SE and MB vs. warfarin and variable risk of stroke/SE and MB against each other.
Source: Journal of Thrombosis and Thrombolysis - May 17, 2022 Category: Hematology Source Type: research
Recommendations for thromboprophylaxis in the 2012 focused update of the ESC guidelines on atrial fibrillation: A commentary
The objective of this article is to provide a commentary on the recommendations for stroke prevention from the 2012 focused update of the European Society of Cardiology guidelines on the management of atrial fibrillation and the evidence (or lack of it) supporting these recommendations.
These guidelines strongly advocate a major clinical practice shift towards initially focusing on the identification of ‘truly low risk’ patients who do not need any antithrombotic therapy. After this initial decision‐making step, effective stroke prevention – that is, oral anticoagulation therapy (whether as well controlled adjusted...
Source: Journal of Thrombosis and Haemostasis - March 2, 2013 Category: Hematology Authors: Gregory Y H Lip Tags: Review Article Source Type: research
Impact of double‐blind versus open study design on the observed treatment effects of new oral anticoagulants in atrial fibrillation: a meta‐analysis
ConclusionsOur meta‐analysis showed no significant interaction of study design for the main efficacy and safety outcomes. However, the non‐significantly exaggerated reduction in SSE suggests interdependence of treatment effect and PROBE design, especially for haemorrhagic stroke.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - May 9, 2013 Category: Hematology Authors: Jean‐Christophe Lega, Patrick Mismetti, Michel Cucherat, Thomas Fassier, Laurent Bertoletti, Céline Chapelle, Silvy Laporte Tags: Original Article ‐ Cardiovascular Medicine Source Type: research
Impact of double‐blind vs. open study design on the observed treatment effects of new oral anticoagulants in atrial fibrillation: a meta‐analysis
ConclusionsOur meta‐analysis showed no significant interaction of study design for the main efficacy and safety outcomes. However, the non‐significantly exaggerated reduction in SSE suggests interdependence of treatment effect and PROBE design, especially for hemorrhagic stroke.
Source: Journal of Thrombosis and Haemostasis - July 15, 2013 Category: Hematology Authors: J.‐C. Lega, P. Mismetti, M. Cucherat, T. Fassier, L. Bertoletti, C. Chapelle, S. Laporte Tags: Original Article Source Type: research
D‐dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation – observations from the ARISTOTLE trial
ConclusionIn anticoagulated patients with AF the level of D‐dimer is related to the risk of stroke, death and bleeding and adds to the predictive value of clinical risk scores. The benefits of apixaban were consistent regardless of the baseline D‐dimer level.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - June 18, 2014 Category: Hematology Authors: Christina Christersson, Lars Wallentin, Ulrika Andersson, John H Alexander, Jack Ansell, Raffaele Caterina, Bernard J Gersh, Christopher B Granger, Michael Hanna, John D Horowitz, Kurt Huber, Steen Husted, Elaine M Hylek, Renato D Lopes, Agneta Siegbahn Tags: Original Article ‐ Clinical Haemostasis and Thrombosis Source Type: research
D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation - observations from the ARISTOTLE trial.
CONCLUSION: In anticoagulated patients with AF the level of D-dimer is related to the risk of stroke, death and bleeding and adds to the predictive value of clinical risk scores. The benefits of apixaban were consistent regardless of the baseline D-dimer level. This article is protected by copyright. All rights reserved.
PMID: 24942912 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - June 18, 2014 Category: Hematology Authors: Christersson C, Wallentin L, Andersson U, Alexander JH, Ansell J, De Caterina R, Gersh BJ, Granger CB, Hanna M, Horowitz JD, Huber K, Husted S, Hylek EM, Lopes RD, Siegbahn A Tags: J Thromb Haemost Source Type: research
Comparative Efficacy and Safety of the Non–Vitamin K Antagonist Oral Anticoagulants for Patients with Nonvalvular Atrial Fibrillation
Semin Thromb HemostDOI: 10.1055/s-0035-1544156The non–vitamin K antagonist oral anticoagulants (NOACs), such as the thrombin inhibitor (dabigatran) and the direct factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban), have been shown to be at least as efficacious and safe as conventional oral anticoagulants, such as the vitamin K antagonists (VKAs) (e.g., warfarin), for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). Each NOAC has various advantages and specific features, and therefore decisions regarding appropriate stroke prevention require individual assessment of stroke and bleeding ri...
Source: Seminars in Thrombosis and Hemostasis - February 15, 2015 Category: Hematology Authors: Senoo, KeitaroLip, Gregory Y. H. Source Type: research
A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
In conclusion, compared with warfarin, dabigatran treatment was associated with a lower risk of stroke and most outcomes measured, but increased incidence of major lower GI bleeding.
PMID: 26446456 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - October 8, 2015 Category: Hematology Authors: Villines TC, Schnee J, Fraeman K, Siu K, Reynolds MW, Collins J, Schwartzman E Tags: Thromb Haemost Source Type: research
D-dimer and factor VIIa in atrial fibrillation - prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy.
We examined baseline levels of D-dimer and their association with stroke, cardiovascular death and major bleeding in 6,202 AF patients randomised to dabigatran or warfarin in the RE-LY trial. The effects of treatment on serial levels of D-dimer and coagulation factor (F) VIIa in 2,567 patients were also analysed. Baseline D-dimer levels were related to the rate of stroke/systemic embolism (SEE) with 0.64 % in the lowest quartile (Q1, as reference) (D-dimer < 298 µg/l), 1.38 % Q2 (D-dimer 298-473 µg/l), 1.71 % Q3 (D-dimer 474-822 µg/l) and 2.00 % in Q4 (D-dimer > 822 µg/l) (p=0.0007). Similar associati...
Source: Thrombosis and Haemostasis - January 28, 2016 Category: Hematology Authors: Siegbahn A, Oldgren J, Andersson U, Ezekowitz MD, Reilly PA, Connolly SJ, Yusuf S, Wallentin L, Eikelboom JW Tags: Thromb Haemost Source Type: research
Anticoagulants Resumption after Warfarin-Related Intracerebral Haemorrhage: The Multicenter Study on Cerebral Hemorrhage in Italy (MUCH-Italy).
In conclusion, in patients who have an ICH while receiving warfarin, resuming anticoagulation results in a favorable trade-off between bleeding susceptibility and thromboembolic risk.
PMID: 29433151 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - February 12, 2018 Category: Hematology Authors: Poli L, Grassi M, Zedde M, Marcheselli S, Silvestrelli G, Sessa M, Zini A, Paciaroni M, Azzini C, Gamba M, Toriello A, Tassi R, Giorli E, Calabrò RS, Ritelli M, De Vito A, Pugliese N, Martini G, Lanari A, Lodigiani C, Padroni M, De Giuli V, Caria F, Moro Tags: Thromb Haemost Source Type: research
Real World Experience of Direct Oral Anticoagulants with Comparison of Safety Outcomes to the Warfarin Era of Venous Thromboembolism Treatment
Conclusion:This retrospective audit shows that our local safety outcomes are comparable to clinical trials. Low dose anticoagulation and high falls risk (a surrogate marker of frailty) were significant risk factors for both clinically significant bleeding and thrombotic stroke in the DOAC population. These patients are likely frailer with greater co-morbidities and have shared risk factors for bleeding and stroke, suggesting that for these high risk patients, low dose anticoagulation does not negate their risk of complications and careful prescribing and close monitoring remain essential.The sub-comparison between VTE pati...
Source: Blood - November 21, 2018 Category: Hematology Authors: Brook, R., Aswapanyawongse, N., Lim, H. Y., Ho, P. Tags: 331. Pathophysiology of Thrombosis: Poster II Source Type: research
Indications, Efficacy and Complications of Kcentra Use in Reversing Coagulopathy
ConclusionsKcentra was used in several off-label clinical settings, with comparable mortality among the coumadin, rivaroxaban and apixaban groups and no identifiable benefit in the setting of cirrhosis, DIC or antiplatelet medications, but with an increased incidence of deep vein thrombosis and stroke.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - November 21, 2018 Category: Hematology Authors: Sritharan, N., Triulzi, D. Tags: 401. Basic Science and Clinical Practice in Blood Transfusion: Poster III Source Type: research
